Impressions From TROPION-Lung05: Dato-DXd in Heavily Pretreated Advanced NSCLC

Author(s):

Jonathan Riess, MD, MS, UC Davis Comprehensive Cancer Center,Christine Bestvina, MD, University of Chicago

This episode discusses the impressive ORR of more than 40% from the phase 2 TROPION-Lung05 trial of Dato-DXd in patients with EGFR-mutated advanced NSCLC, its clinical impact on those treated with 3 or more prior therapies, and explores the potential of Dato-DXd as a practice-changing therapy, given the median DOR of 7 months and DCR of 79%.

EP: 1.Clinical Insights on Osimertinib in Frontline Therapy for EGFR-Mutated NSCLC

EP: 2.Optimizing Treatment for Advanced EGFR-Mutated NSCLC: FLAURA2, Toxicity Management, and ctDNA

EP: 3.ADAURA Trial Findings: Outcomes and CNS Involvement in EGFR-Mutated NSCLC

EP: 4.Osimertinib in Resected Stage IB to IIIA NSCLC: Perspectives on Its Use for Less Common EGFR Mutations

EP: 5.Tailoring Treatment by Stage: Insights From ADAURA for Stage IB to IIIA EGFR-Mutated NSCLC

EP: 6.Targeted ADCs vs Chemotherapy in Heavily Pretreated NSCLC: Clinical Benefits and Challenges

EP: 7.Role of Datopotamab Deruxtecan in Advanced NSCLC: Insights From TROPION-Lung01

EP: 8.Managing Toxicities With TROP2-Directed ADCs in Advanced NSCLC: Best Practices and Management Strategies

Now Viewing

EP: 9.Impressions From TROPION-Lung05: Dato-DXd in Heavily Pretreated Advanced NSCLC

EP: 10.Adverse Event Management and Resistance Mechanisms: Key Considerations for Datopotamab Deruxtecan in Advanced NSCLC

EP: 11.Evaluating Response Rates in HERTHENA-Lung01: Insights on HER3-DXd

EP: 12.Integrating HER3-DXd: Clinical Considerations for Future Approval and Implementation in Practice

Video content above is prompted by the following:

From the primary results of the phase 2 TROPION-Lung05 trial, please share your impressions of the ORR of greater than 40% among patients with EGFR-mutated advanced or metastatic NSCLC.
From a clinical practice perspective, how impactful is this response rate, particularly among patients who had received 3or more lines of prior therapy?